Market closed
AnaptysBio/$ANAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Ticker
$ANAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
136
Website
AnaptysBio Metrics
BasicAdvanced
$538M
-
-$5.12
0.02
-
Price and volume
Market cap
$538M
Beta
0.02
52-week high
$41.31
52-week low
$12.21
Average daily volume
1.2M
Financial strength
Current ratio
9.507
Quick ratio
9.381
Long term debt to equity
518.623
Total debt to equity
521.34
Interest coverage (TTM)
-2.29%
Management effectiveness
Return on assets (TTM)
-15.35%
Return on equity (TTM)
-182.71%
Valuation
Price to revenue (TTM)
5.454
Price to book
7.54
Price to tangible book (TTM)
7.54
Price to free cash flow (TTM)
-3.669
Growth
Revenue change (TTM)
432.03%
Earnings per share change (TTM)
-15.80%
3-year revenue growth (CAGR)
13.05%
3-year earnings per share growth (CAGR)
34.42%
What the Analysts think about AnaptysBio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.
AnaptysBio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AnaptysBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AnaptysBio News
AllArticlesVideos
Anaptys Announces Participation in March Investor Conferences
GlobeNewsWire·2 weeks ago
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 weeks ago
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AnaptysBio stock?
AnaptysBio (ANAB) has a market cap of $538M as of March 13, 2025.
What is the P/E ratio for AnaptysBio stock?
The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of March 13, 2025.
Does AnaptysBio stock pay dividends?
No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next AnaptysBio dividend payment date?
AnaptysBio (ANAB) stock does not pay dividends to its shareholders.
What is the beta indicator for AnaptysBio?
AnaptysBio (ANAB) has a beta rating of 0.02. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.